
In a study of over 1,000 eyes treated for neovascular age-related macular degeneration (nAMD), diabetic patients—especially those with moderate diabetic retinopathy—showed a significantly higher persistence of subretinal fluid (SRF) after anti-VEGF therapy. While visual and retinal thickness outcomes improved in all patients, diabetes appears to hinder full anatomical response.
Like
Save
Share